Research programme: HIV tat inhibitors - Amgen

Drug Profile

Research programme: HIV tat inhibitors - Amgen

Alternative Names: HIV tat inhibitors research programme - Amgen

Latest Information Update: 09 Dec 2003

Price : $50

At a glance

  • Originator Tularik
  • Class Small molecules
  • Mechanism of Action HIV replication inhibitors; Human immunodeficiency virus tat gene product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Dec 2003 Discontinued - Preclinical for HIV infections treatment in USA (PO)
  • 10 Mar 1999 Preclinical development for HIV infections treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top